Key result
Nebivolol and atenolol both reduced blood pressure, but atenolol elevated mean blood sugar and lipid profiles whereas nebivolol did not.
Why the study?
Does nebivolol improve metabolic parameters compared to atenolol in patients with essential hypertension?
RCT (n=69)
Open-label
parallel
Does nebivolol improve metabolic parameters compared to atenolol in patients with essential hypertension?
Nebivolol provides similar antihypertensive efficacy to atenolol but avoids the adverse metabolic effects on blood sugar and lipid profiles associated with traditional beta-blockers.
Answers are grounded in this paper and cite their sources.
Nebivolol may be metabolically preferable to atenolol; leaves open need for larger trials before practice change.
BACKGROUND: Nebivolol is a third-generation β-blocker, with highest β(1) selectivity and nitric-oxide-derived vasodilatation. It also exhibits antiproliferative and antioxidant property that has beneficial metabolic profile compared to second-generation β blockers like atenolol. This study was planned to study the comparative effects of nebivolol and atenolol on metabolic parameters in patients with essential hypertension. MATERIALS AND METHODS: A prospective, randomized, parallel, open-label clinical study was carried out on patients with essential hypertension. The patients were randomly assigned to receive tablet atenolol (Group A) and nebivolol (Group B) for a period of 24 weeks. Investigations were carried out at baseline and at the end of study period, that is, 24 weeks. Out of 69 patients, 60 completed the study and the data was analyzed using student's t-test. P < 0.05 was considered statistically significant. RESULTS: Atenolol and nebivolol both showed significant (P < 0.001) antihypertensive action after 24 weeks. Mean blood sugar and lipid profile were found to be significantly (P < 0.001) elevated after 24 weeks of treatment with atenolol but not with nebivolol. Heart rate was significantly (P < 0.001) decreased in both groups at 24 weeks. CONCLUSION: In view of metabolic adverse effects of atenolol, nebivolol is the better choice whenever β-blockers have to be used in essential hypertension.
No takes yet. Share an insight, caveat, or question.
Badar et al. (2011) conducted an RCT in essential hypertension (n=69). Nebivolol vs. Atenolol was evaluated on blood pressure, blood sugar, and lipid profile (p=<0.001). Nebivolol and atenolol both reduced blood pressure, but atenolol elevated mean blood sugar and lipid profiles whereas nebivolol did not.
Synapse has enriched 10 related papers. Consider them for comparative context: